Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04856884 (CVX-060) plus Axitinib in previously treated metastatic renal cell carcinoma
2011-002190-33Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Nov 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of PF-04856884 and axitinib in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by Pfizer. Primary endpoint: Part I maximum tolerated dose of CVX-060 + axitinib. Started Nov 2011; status: terminated.
02
Drugs
PF-04856884axitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2011-002190-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002190-33.